In this episode, Jason Schafer, PharmD, MPH, explores key considerations for the use of long-acting injectable pre-exposure prophylaxis (PrEP).- Listen as he gives his perspectives on:- The FDA approval of long-acting cabotegravir for PrEP- Healthcare professionals’ clinical concerns with long-acting injectable antiretroviral therapy- Considerations for long-acting cabotegravir as PrEPDosing and administrationManaging missed dosesDiscontinuationDelays in HIV diagnoses found in the HPTN 083 study in men- CDC recommendations for HIV screening while receiving PrEPPresenter:Jason Schafer, PharmD, MPHProfessor and Vice ChairJefferson College of PharmacyThomas Jefferson UniversityPhiladelphia, Pennsylvania  Follow along with the slides at: https://bit.ly/3wugMOCSee the entire program at: https://bit.ly/3q2DlGd